Navigation Links
Angiotech and Symphony Medical Announce Licensing Agreement
Date:1/17/2008

New Clinical Program Under Development to Improve Outcomes of Coronary

Artery Bypass Grafting (CABG) and Cardiac Valve Surgeries

VANCOUVER, BC and LAGUNA HILLS, CA, Jan. 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) and privately held Symphony Medical, Inc. today announced that they have entered into an exclusive licensing agreement to employ one of Angiotech's proprietary PEG-based biomaterials as part of a prophylactic therapy envisioned to mitigate the onset of post-operative atrial fibrillation (POAF) for patients undergoing coronary artery bypass grafting and cardiac valve surgeries.

"This agreement is another example of our continuing effort to lessen the complications and improve the outcomes of patients living with cardiovascular disease," said Dr. Bill Hunter, President and CEO of Angiotech. "Our innovative use of cutting edge, site-specific therapy has been central to the development of coronary and peripheral drug-eluting stents, anti-restenosis therapy in bypass surgery and hemodialysis access procedures, and more recently, coronary stem cell therapy and treatments for arrhythmias following open heart surgery," added Dr. Hunter.

Symphony Medical has been engaged in the development of non-destructive biocompatible polymer therapies to treat significant cardiac conditions such as atrial fibrillation and congestive heart failure since 2003. Its lead program involves the development of a prophylactic injection of biopolymer to prevent or reduce the incidence of POAF that occur following coronary artery bypass grafting (CABG) and cardiac valve surgeries. The product under development is a kit which employs a biopolymer, applicator and specialized electrical stimu
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
2. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
3. Angiotech to participate in RBC 2007 Healthcare Conference
4. Angiotech to participate in Bank of America 2007 Credit Conference
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
8. Angiotech to participate in UBS Global Life Sciences Conference
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... ended March 31, 2015.  Biorem,s complete 2015 first quarter financial statements ... Financial Summary:Three-months ended March 31,(in CDN$,000 except per ... 4,689 , 1,974 Gross profit , 1,531 ... (318) Net earnings (loss) , 528 , (531) ...
(Date:6/1/2015)... , June 1, 2015 ... announced the addition of the "Global PDT ... offering.        (Logo: ... Report 2014 is a professional and in-depth study ... , ,The report provides a basic overview of ...
(Date:6/1/2015)... Regis Technologies, Inc. is a ... stationary phases (CSPs) for analytical and preparative chromatography ... presenting solutions for new clients, Regis implemented a ... addition to its core expertise in chiral chromatography ... tackle projects for the scale clients need–from milligram ...
(Date:6/1/2015)... RESEARCH TRIANGLE PARK, N.C. , June 1, ... FENCF), announced the presentation of positive interim results ... in SIOPEL6: A multi-centre open label randomised phase ... (STS) in reducing ototoxicity in patients receiving cisplatin ... data was presented at the American Society of ...
Breaking Biology Technology:Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Global PDT Machine Industry Report 2014 2Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4
... Inc., (Nasdaq: MGRM ) announced that it will ... 4:30 p.m. (Eastern Time) to discuss,third quarter 2007 financial ... Young, Chairman and CEO of Monogram. To participate ... 325-4878 for international callers, fifteen minutes before the,conference begins. ...
... Oct. 17 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) ... 30, 2007. Total revenues in the third quarter ... the third quarter of 2006. Total revenues in the ... $25.9 million in the,first nine months of 2006. Revenues ...
... Diplomat Health Services,in conjunction with McLaren Health Plan, ... Genzyme, announced today the results of its,pilot program ... The,program managed chronic kidney disease patients for McLaren ... savings of $300 per patient per,month compared to ...
Cached Biology Technology:Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 7Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management 2
(Date:5/22/2015)... May 22, 2015 According to ... Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), ... and Utilities, Consumer and Home) - Global Forecast to ... from $2.77 Billion in 2015 to $6.19 Billion by ... Browse 79 market data Tables and   43 Figures ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
(Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... developed in part by DOE,s Oak Ridge National Laboratory ... threats of insects, disease and wildfire. Led by ... computing to incorporate remote sensing data from NASA satellites ... abnormal vegetation patterns and the timing of seasonal changes. ...
... of Understanding signed today, the European Commission (EC) and ... to maintain and further develop their cooperation. , "I ... of Understanding between the European Commission and the European ... set the stage for even better and more fruitful ...
... , This release is available in Spanish ... Linoleico Conjugado y Resvetratrol: efecto de estos ingredientes funcionales sobre ... Linoleic Acid and Resveratrol: the effect of these functional ingredients ... research team member at the University of the Basque Country ...
Cached Biology News:Resveratrol may be useful tool for reducing body fat 2